177Lu-PSMA-617与卡巴他赛相比,在PSA降低≥50% (66% vs 37%)与应答率(49% vs 24%)上均具有统计学意义。 ASCO建议 基于此前数个研究,专家组建议:对之前使用过一种雄激素受体抑制剂和至少一种化疗药物,且PSMA PET/ CT阳性的mCRPC患者,将177Lu-PSMA-617 IV作为此类患者的一种治疗选择,每6周1次,应用4-...
在Journal of Clinical Oncology杂志2022年11月刊上,美国临床肿瘤学会(ASCO)成员发表题为“Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer:ASCO Rapid Recommendation”2的文章,对ASCO指南修订提出建议,介绍在mCRPC应用177Lu-PSMA-617的疗效与优点。 FDA批准该疗法主要...
In a Phase 2 clinical trial, we aimed to determine the lutetium-177 [Lu]-PSMA-617 activity and the clinical utility of levels of plasma androgen receptor (AR) gene in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).We determined AR copy number in ...
According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting. “With the announcement of these positive topline phase ...
lu-psma-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (therap): a randomised, open-label, phase 2 trial lancet, 397 (10276) (2021), pp. 797-804 view in scopus google scholar 11 p.s. choudhury, m. gupta precision oncology through radiating bullets: ...
This trial is registered with ClinicalTrials.gov, NCT03392428. Findings Between Feb 6, 2018, and Sept 3, 2019, we screened 291 men, of whom 200 were eligible on PET imaging. Study treatment was received by 98 (99%) of 99 men randomly assigned to [ Lu]Lu-PSMA-617 versus 85 (84%)...
The protocol aimed at four cycles of 6.0–7.4 GBq 177Lu-PSMA-617 every 6–8 weeks. Clinical response was evaluated by questionnaires and radiological response by 68Ga-PSMA-PET/CT. Results Six patients were treated with 177Lu-PSMA: four adenoid cystic carcinomas, one adenocarcinoma NOS and ...
Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to th...
将177Lu-FAP-2286与之前报道的其他有效的放射性药物(治疗神经内分泌肿瘤的177Lu-DOTATATE和治疗前列腺癌的177Lu-PSMA-617)相比较,其在全身、骨髓和肾脏的吸收剂量具有可比性。值得注意的是,177Lu-FAP-2286在没有肾脏保护的情况下,其肾...
本次公布的数据显示,前列腺特异性膜抗原(PSMA)靶向小分子放射性配体由基于谷氨酸脲的药源组成,通过连接体连接到DOTAGA放射性金属螯合剂上,经盲法独立中央审查,中位rPFS为9.5个月,而APRI为6.0个月;这意味着放射学进展或死亡风险降低了29%(HR,0.71;P=.0088)。在进行分析时,总生存期(OS)的危险比为1.11;但数据尚...